STOK · Stoke Therapeutics, Inc.
$29.30
+0.27% last session
End-of-day data · updated 2026-07-28
Market cap
$2B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-9.5
Dividend yield
—
Beta
1.18
Avg volume
1M
Employees
0K
2D change
0.03%
5D change
-1.15%
10D change
0.90%
30D change
-8.41%
60D change
-5.18%
MTD change
-10.39%
YTD change
-7.66%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — STOK
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-13
Latest call per bank · past 12 months
Goldman Sachs
Buy$44.00
+50.2% vs priceJP Morgan
Neutral$25.00
-14.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-13 | Goldman Sachs | Initiates | Buy | $0.00 → $44.00 |
| 2026-05-11 | BTIG | Reiterates | Buy | $39.00 |
| 2026-03-20 | Canaccord Genuity | Maintains | Buy | $36.00 → $60.00 |
| 2026-03-19 | BTIG | Reiterates | Buy | $39.00 |
| 2026-03-18 | Wedbush | Maintains | Outperform | $36.00 → $38.00 |
| 2026-03-18 | Chardan Capital | Maintains | Buy | $35.00 |
| 2026-03-17 | Wedbush | Maintains | Outperform | $36.00 → $38.00 |
| 2026-03-17 | Needham | Maintains | Buy | $35.00 → $40.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 45 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 3.2% below the 50-day MA ($30.36).
- Price vs 200-day MA: Trading 7.2% below the 200-day MA ($31.67).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.13) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($12.50) and high ($38.35).
STOK Price Chart
Loading chart for STOK…
Fundamentals
About Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.